Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Strepsils Extra Triple Action Blackcurrant Lozenges

Active Ingredient:
Reckitt Benckiser Healthcare (UK) Ltd See contact details
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 25 Aug 2021
1. Name of the medicinal product

Strepsils Extra Blackcurrant Lozenges

Strepsils Extra Triple Action Blackcurrant Lozenges

Strepsils Extra Strength Blackcurrant Lozenges

2. Qualitative and quantitative composition

Each lozenge contains Hexylresorcinol 2.4mg

Excipient(s) with known effect:


Fragrance containing allergens - d-Limonene and Linalool**

Carmoisine (E122)


Sulphites – Sulphur Dioxide (E220)*

Wheat starch (containing Gluten)*

Propylene glycol **

* present in liquid glucose

** present in blackcurrant flavour

For excipients see Section 6.1

3. Pharmaceutical form


A round purple lozenge

4. Clinical particulars
4.1 Therapeutic indications

As an antiseptic and local anaesthetic for the relief of sore throat and its associated pain.

4.2 Posology and method of administration

For oral administration.

Adults, the elderly and children 6 years and over: One lozenge dissolved slowly in the mouth every three hours or as required.

Do not take more than 12 lozenges in 24 hours.

Not to be given to children under 6 years.

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

The label will convey:

Keep out of the reach and sight of children.

If symptoms persist consult your doctor.

Not to be given to children under 6 years.

Important information about some of the ingredients of this medicine

• This medicine contains only very low levels of gluten (from wheat starch). It is regarded as 'gluten-free' and is very unlikely to cause problems if you have coeliac disease.

One lozenge contains no more than 22.42 micrograms of gluten.

If you have wheat allergy (different from coeliac disease) you should not take this medicine.

• This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

• This medicine contains fragrance with d-Limonene and Linalool.

d-Limonene and Linalool may cause allergic reactions.

• This medicine contains carmoisine (E122) which may cause allergic reactions

• This medicine contains Sulphites – Sulphur Dioxide (E220) – present in liquid glucose which may rarely cause severe hypersensitivity reactions and bronchospasm.

• Patients with rare glucose-galactose malabsorption should not take this medicine

• Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Pregnancy and lactation

There is lack of evidence of safety of the product in human pregnancy and in animals, but hexylresorcinol has been used widely in lozenges for many years without apparent ill consequence. However, as with all medicines, caution should be exercised during pregnancy and lactation.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

System Organ Class


Adverse Events

Immune System Disorders

Not known


1 Hypersensitivity reactions may include rash, urticaria and angioedema, which may include swelling of the face, neck, throat or tongue that could affect breathing.

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Hexylresorcinol overdosage may cause minor gastrointestinal irritation. Treatment would be withdrawal of the product and symptomatic measures as appropriate.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Hexylresorcinol is a local anaesthetic for topical use on the mucous membranes of the mouth and throat. Mild antiseptic activity has also been demonstrated.

The product base has a demulcent action.

5.2 Pharmacokinetic properties

Pharmacokinetic considerations do not arise since the pharmacological action is local to the oro-pharyngeal cavity.

5.3 Preclinical safety data

There are no preclinical data of relevance additional to those already included in other sections of the SPC.

6. Pharmaceutical particulars
6.1 List of excipients

Liquid sucrose

Liquid glucose (prepared from wheat starch (containing gluten) and Sulphites – Sulphur Dioxide)

Blackcurrant flavour (containing Propylene glycol, d-Limonene and Linalool)


Carmoisine (E122)

Patent blue V (E131)

6.2 Incompatibilities

Not applicable

6.3 Shelf life

36 months for the unopened blister pack

6.4 Special precautions for storage

Do not store above 25° C. Store in the original packaging. Keep in the outer carton.

6.5 Nature and contents of container

Blister packs of 250 micron PVC/coated 40gsm PVDC with 20 micron hard temper aluminium foil heat-sealed to the PVC/PVDC blister. The tray contains an appropriate number of lozenges to give a pack sizes of 2, 4, 6, 12, 16, 24, 32, 36 and 48.

8 lozenges in a blister in a carton or a flow wrap outer composed of PET/aluminium foil/polyethylene.

6.6 Special precautions for disposal and other handling

None specific to the product/pack.

7. Marketing authorisation holder

Reckitt Benckiser Healthcare (UK) Ltd



8. Marketing authorisation number(s)

PL 00063/0392

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text


Reckitt Benckiser Healthcare (UK) Ltd
Company image
RB Consumer Relations, PO Box 4644, SLOUGH, SL1 0NS, UK
0333 2005 345
Medical Information Direct Line
0333 2005 345
Customer Care direct line
0333 2005 345